Literature DB >> 31757313

Precision Medicine and Targeted Therapies in Breast Cancer.

Ian Greenwalt1, Norah Zaza2, Shibandri Das1, Benjamin D Li3.   

Abstract

Precision medicine and targeted therapies have a long history in the treatment of breast cancer and continue to show promise for further specialized and individualized care for this disease. From the discovery of endocrine and HER2 targeted therapies, to multigene arrays in chemotherapy for more specific patient selection, to radiomics and genetic subtyping, targeted therapies and precision medicine continue to push the management of breast cancer toward more individualized care. This article describes the foundation and future of targeted therapy and precision medicine in breast cancer.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer; Endocrine therapy; Genomics; HER2; Multigene array; Precision medicine; Radiomics; Targeted therapy

Year:  2019        PMID： 31757313     DOI： 10.1016/j.soc.2019.08.004

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN： 1055-3207            Impact factor:   3.495


  11 in total

Review 1.  Overcoming resistance to targeted therapy using MET inhibitors in solid cancers: evidence from preclinical and clinical studies.

Authors:  Nehad M Ayoub; Dalia R Ibrahim; Amer E Alkhalifa
Journal:  Med Oncol       Date:  2021-10-19       Impact factor: 3.064

2.  Proteomic Profiles of Neurodegeneration Among Mexican Americans and Non-Hispanic Whites in the HABS-HD Study.

Authors:  Sid E O'Bryant; Fan Zhang; Melissa Petersen; James R Hall; Leigh A Johnson; Kristine Yaffe; Meredith Braskie; Rocky Vig; Arthur W Toga; Robert A Rissman
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

3.  Development and interpretation of a QSAR model for in vitro breast cancer (MCF-7) cytotoxicity of 2-phenylacrylonitriles.

Authors:  David T Stanton; Jennifer R Baker; Adam McCluskey; Stefan Paula
Journal:  J Comput Aided Mol Des       Date:  2021-05-04       Impact factor: 3.686

4.  USP41 promotes breast cancer via regulating RACK1.

Authors:  Meiling Huang; Jingjing Xiao; Changjiao Yan; Ting Wang; Rui Ling
Journal:  Ann Transl Med       Date:  2021-10

5.  Construction and Validation of Angiogenesis-Related Prognostic Risk Signature to Facilitate Survival Prediction and Biomarker Excavation of Breast Cancer Patients.

Authors:  Yingkun Xu; Yang Peng; Meiying Shen; Li Liu; Jinwei Lei; Shun Gao; Yuan Wang; Ailin Lan; Han Li; Shengchun Liu
Journal:  J Oncol       Date:  2022-04-20       Impact factor: 4.501

6.  Molecular Spectra and Frequency Patterns of Somatic Mutations in Arab Women with Breast Cancer.

Authors:  Humaid O Al-Shamsi; Ibrahim Abu-Gheida; Ahmed S Abdulsamad; Aydah AlAwadhi; Sadir Alrawi; Khaled M Musallam; Banu Arun; Nuhad K Ibrahim
Journal:  Oncologist       Date:  2021-08-14

Review 7.  Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells.

Authors:  Abdulaziz B Hamid; Ruben C Petreaca
Journal:  Cancers (Basel)       Date:  2020-04-09       Impact factor: 6.639

8.  SKA3 Promotes Cell Growth in Breast Cancer by Inhibiting PLK-1 Protein Degradation.

Authors:  Li-Wei Ruan; Peng-Peng Li; Lang-Ping Jin
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

9.  Long noncoding RNA ZBED3-AS1 restrains breast cancer progression by targeting the microRNA-513a-5p/KLF6 axis.

Authors:  Aiqin Fu; Ze Yu; Enning Zhang; Jijie Song
Journal:  Thorac Cancer       Date:  2021-08-24       Impact factor: 3.500

10.  KCTD15 Is Overexpressed in her2+ Positive Breast Cancer Patients and Its Silencing Attenuates Proliferation in SKBR3 CELL LINE.

Authors:  Luigi Coppola; Simona Baselice; Francesco Messina; Rosa Giannatiempo; Amalia Farina; Luigi Vitagliano; Giovanni Smaldone; Marco Salvatore
Journal:  Diagnostics (Basel)       Date:  2022-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.